GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Price-to-Owner-Earnings

LadRx (LADX) Price-to-Owner-Earnings

: 1.06 (As of Today)
View and export this data going back to 1986. Start your Free Trial

As of today (2024-04-19), LadRx's share price is $2.12. LadRx's Owner Earnings per Share (TTM) ended in Dec. 2023 was $2.00. It's Price-to-Owner-Earnings for today is 1.06.


The historical rank and industry rank for LadRx's Price-to-Owner-Earnings or its related term are showing as below:

LADX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0   Med: 0   Max: 5.36
Current: 1.06

During the past 13 years, the highest Price-to-Owner-Earnings of LadRx was 5.36. The lowest was 0.00. And the median was 0.00.


LADX's Price-to-Owner-Earnings is ranked better than
98.87% of 177 companies
in the Biotechnology industry
Industry Median: 33.62 vs LADX: 1.06

As of today (2024-04-19), LadRx's share price is $2.12. LadRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.11. Therefore, LadRx's PE Ratio for today is At Loss.

As of today (2024-04-19), LadRx's share price is $2.12. LadRx's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.11. Therefore, LadRx's PE Ratio without NRI for today is At Loss.

During the past 13 years, LadRx's highest PE Ratio without NRI was 92.00. The lowest was 0.00. And the median was 74.25.


LadRx Price-to-Owner-Earnings Historical Data

The historical data trend for LadRx's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.65

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.86 0.65

Competitive Comparison

For the Biotechnology subindustry, LadRx's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, LadRx's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where LadRx's Price-to-Owner-Earnings falls into.



LadRx Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

LadRx's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.12/2.00
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LadRx  (OTCPK:LADX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


LadRx Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of LadRx's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049

LadRx (LADX) Headlines

From GuruFocus

CytRx Corporation Provides Update on Management Change

By PRNewswire PRNewswire 03-10-2020

CytRx Corporation to Commence Trading on OTCQB Venture Market

By PRNewswire PRNewswire 05-31-2019

CytRx Corporation Reports Third Quarter 2018 Financial Results

By PRNewswire PRNewswire 11-02-2018